Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

298.08 +9.90 (+3.44%)

Streaming Delayed Price Updated: 3:35 PM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

21 22 Next >

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

March 05, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 29, 2024

Via Benzinga

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

February 28, 2024

Via Benzinga

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

February 27, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Alnylam Pharmaceuticals's Earnings Outlook ↗

February 14, 2024

Via Benzinga

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

February 06, 2024

Via Benzinga

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know ↗

February 16, 2024

Via Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday? ↗

February 15, 2024

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

Via Benzinga

Why Alnylam Pharmaceuticals Stock Is Sinking Today ↗

February 15, 2024

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

Via The Motley Fool

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

February 15, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Analyst Expectations for Alnylam Pharmaceuticals's Future ↗

December 08, 2023

Via Benzinga

Expert Ratings for Alnylam Pharmaceuticals ↗

November 15, 2023

Via Benzinga

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results

January 29, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again ↗

January 12, 2024

There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.

Via Investor's Business Daily

Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association

January 09, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates

January 07, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗

January 04, 2024

A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗

December 29, 2023

Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.

Via Benzinga

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

December 13, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

Via MarketBeat

Topics ETFs

Alnylam to Webcast Virtual R&D Day

December 06, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Why Newly Listed Korro Bio Shares Are Gaining Today ↗

December 04, 2023

H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.

Via Benzinga

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023

November 30, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

November 11, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws ↗

November 08, 2023

San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.